The role of the conventional drugs in the treatment of the rheumatoid arthritis;Il ruolo dei farmaci "tradizionali" nella terapia dell'artrite reumatoide

Recenti Progressi in Medicina

Volumn 94, Issue 7-8, 2003, Pages 330-338

  Fantini, Flavio ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b Ctro di Chir Artrite Reumatoide   (Italy)

Author keywords

Disease modifyng antirheumatic drugs; Glucocorticoids; Methotrexate; Non steroidal anti inflammatory drugs; Rheumatoid arthritis; Sulfasalazine

Indexed keywords

ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AURANOFIN; CELECOXIB; CHLOROQUINE; CYCLOSPORIN A; DICLOFENAC; GLUCOCORTICOID; INDOMETACIN; METHOTREXATE; MINOCYCLINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISONE; ROFECOXIB; SALAZOSULFAPYRIDINE;

DISABILITY; HUMAN; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; TREATMENT PLANNING;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CONTROLLED CLINICAL TRIALS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; GOLD COMPOUNDS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; MINOCYCLINE; PROGNOSIS; QUESTIONNAIRES; SULFASALAZINE; TIME FACTORS;

EID: 0042977570     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Cimmino MA, Parisi M, Moggiana G, Mela GS, Accardo S. Prevalence of rheumatoid arthritis in Italy: The Chiavari Study. Ann Rheum Dis 1998; 57: 315-8.
2. Brooks PM. Clinical management of rheumatoid arthritis. Lancet 1993; 341: 286-90.
3. Tugwell P, Boers M, OMERACT Committee. Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. J Rheumatol 1993; 20: 556-61.
4. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
5. Van Riel PLCM, van Gestel AM. Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis 2000; 59 (suppl 1): i28-i31.
6. Kirwan JR. Conceptual issues in scoring radiographic progression in rheumatoid arthritis. J Rheumatol 1999; 26: 720-5.
7. Edmonds J. DC-ART: the concept. J Rheumatol 1994; 21 (suppl 41): 3-7.
8. Witter J. Drug development in rheumatoid arthritis. Curr Opin Rheumatol 2002; 14: 276-80.
9. US Food and Drug Administration Center for Drug Evaluation and Research. Guidance documents Web site: http://www. Fda.gov/cder/guidance/index.htm. RA guidance document.
10. Van der Heijde DMFM, van't Hof MA, van Riel PLCM, van de Putte LBA. Development of a disease activity score based on judgement in clinical practice by rheumatologists. J Rheumatol 1993; 20: 579-81.
11. Van Gestel AM, Anderson JJ, van Riel PLCM, Boers M, Haaggsma CJ, Rich B, Wells G, Lange MLM, Felson DT. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. J Rheumatol 1999; 26: 705-11.
12. Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 1: The older drugs. Amer J Therap 2001; 8: 123-43.
13. Case JP. Old and new drugs used in rheumatoid arthritis: a historical perspective. Part 2: The newer drugs and drug strategies. Amer J Therap 2001; 8: 163-79.